EOS Imaging has raised US$51 million in its IPO on NYSE Euronext
February 2012 — Venture-backed medical device company EOS Imaging has raised US$51 million in its IPO on NYSE Euronext. Based on the opening trade price, the company is valued at approximately US$146 million. Investors include medical device-focused venture capital firm NBGI Ventures and Edmond de Rothschild Investment Partners, which has been the lead investor and the company’s largest shareholder since 2005.
EOS Imaging designs, develops and markets EOS, a medical imaging system revolutionizing the treatment chain of the main osteoarticular diseases (hips, knees, back) and related orthopedic surgery. Based on the work of Physics Nobel Prize Winner Georges Charpak, the EOS system is the first imaging solution capable of producing, in one step, a 2D and 3D image of the upright skeleton with a very low radiation dose. EOS 2D/3D images are produced in the patient’s natural functional position, raising the accuracy of diagnosis, surgery and osteoarticular pathological follow-up.
The success of the IPO confirms EOS Imaging’s outstanding technology pedigree, its sound commercial and clinical proposition and its potential for strong commercial growth on a global level.
Our role in the transaction
Oaklins’ team in France was appointed by the shareholders of EOS Imaging to launch an initial public offering and proposed listing of the company’s shares on compartment C of the regulated market of NYSE Euronext.
Talk to the deal team
Related deals
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreTandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi
Tandem S.r.l. has completed a voluntary public tender offer for 25.99% of the shares in Compagnia dei Caraibi S.p.A.
Learn moreICOP has transferred its listing from Euronext Growth Milan to Euronext Milan
ICOP S.p.A. has transferred its listing from Euronext Growth Milan to Euronext Milan.
Learn more